Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook

The International Rare Diseases Research Consortium (IRDiRC) has created a Guidebook to facilitate drug development for rare diseases by organizing available tools into a standardized framework.
  1. Anneliene Hechtelt Jonker

    1. IRDiRC, Paris, France.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Virginie Hivert

    1. IRDiRC, Paris, France; EURORDIS-Rare Diseases Europe, Paris, France.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Michela Gabaldo

    1. IRDiRC, Paris, France; Fondazione Telethon, Milan, Italy.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Liliana Batista

    1. IRDiRC, Paris, France; Chiesi Farmaceutici S.p.A., Parma, Italy.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. Daniel O’Connor

    1. IRDiRC, Paris, France; Medicines and Healthcare products Regulatory Agency, London, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  6. Annemieke Aartsma-Rus

    1. IRDiRC, Paris, France; Leiden University Medical Centre, Leiden, The Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  7. Simon Day

    1. IRDiRC, Paris, France; Clinical Trials Consulting and Training Limited, North Marston, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  8. Ken Sakushima

    1. IRDiRC, Paris, France; Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  9. Diego Ardigo

    1. IRDiRC, Paris, France; Chiesi Farmaceutici S.p.A., Parma, Italy.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Millions of people worldwide are affected by rare diseases, but it is estimated that fewer than 5% of the known rare diseases have at least one approved pharmacotherapy1. Regulatory and economic incentives for the development of drugs for rare diseases (orphan drugs), have led to a steady rise in the number of such treatments2, but at the current pace, the International Rare Diseases Research Consortium (IRDiRC)’s goal3 of 1,000 new rare disease therapies by 2027 will not be reached.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 19, 495-496 (2020)

doi: https://doi.org/10.1038/d41573-020-00060-w

Acknowledgements

This article was written on behalf of the IRDiRC ODDG Task Force and Therapies Scientific Committee. The members and contributors beyond the authors were A. Aiuti, D. Athanasiou, L. Conklin, S. Cheng, R. Conwit, M. Driessens, M. Haffner, E. Hoffman, S. Jethwa, E. Matsuki, A. Mingorance, T. Morel, A. Pariser, C. Pontes, M. Scarpa and R. Yang. We would also like to thank A.-L. Pham-Hung d’Alexandry d’Orengiani for her support. The work was supported by the European contracts “SUPPORT-IRDiRC” (N° 305207) and “European Joint Programme on Rare Diseases”(N°825575).

Disclaimer

The views expressed in this article are the personal views of the author(s) and may not be understood as being made on behalf of their employer(s)/organization(s).

References

  1. Nguengang Wakap, S. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 28, 165–173 (2020).

    Article  PubMed  Google Scholar 

  2. Boycott, K. M. & Ardigó, D. Addressing challenges in the diagnosis and treatment of rare genetic diseases. Nat. Rev. Drug Discov. 17, 151–152 (2018).

    Article  PubMed  Google Scholar 

  3. Austin, C. P. et al. Future of rare diseases research 2017–2027: An IRDiRC perspective. Clin. Transl. Sci. 11, 21–27 (2018).

    Article  PubMed  Google Scholar 

  4. Day, S. et al. Recommendations for the design of small population clinical trials. Orphanet J. Rare Dis. 13, 195 (2018).

    Article  PubMed  Google Scholar 

  5. Morel, T. et al. Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet J. Rare Dis. 12, 171 (2017).

    Article  PubMed  Google Scholar 

Download references

Supplementary Information

  1. Supplementary figures

Competing Interests

The authors declare no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links